SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- UWM Holdings Corporation (NYSE: UWMC) faces a securities class action lawsuit after the price of their shares cratered 34% on August 6, 2026 in response to revelations that the company suffered over a $603 million hedge loss associated with its failed bid to acquire Two Harbors Investment Corp. and, as a result, agreed to a plan to massively dilute existing shareholders.

Hagens Berman is investigating the alleged claims and encourages UWM investors who suffered substantial losses to submit your losses now.

Key Details

Class Period: Mar. 9, 2026 – Aug. 5, 2026

Lead Plaintiff Deadline: Oct. 13, 2026

Visit: www.hbsslaw.com/uwmc

Contact the Firm Now: [email protected]

                                        844-916-0895

UWM Holdings Corporation (UWMC) Securities Class Action:

The suit centers on UWM's disclosures about its hedging strategy in connection with its attempt to acquire Two Harbors.

On December 17, 2025, mortgage lender UWM announced that it and mortgage servicing rights ("MSR") company Two Harbors entered into a merger agreement pursuant to which UWM would acquire Two Harbors for about $1.3 billion in UWM stock. Two Harbors was free to receive proposals superior to UWM's.

In connection with the proposed acquisition, UWM entered into significant hedging transactions against Two Harbors' MSR portfolio whose value typically and rapidly changes based on interest rates and homeowner refinancing speeds.

The complaint alleges that UWM did not disclose that it over-hedged in connection with its attempt to take over Two Harbors. The danger to this is that if an acquisition falls through the massive hedge left behind can turn into a speculative gamble.

Over four months ago, on March 27, 2026, Two Harbors announced that it entered a definitive merger agreement with CrossCountry Mortgage in a cash transaction and that it terminated its previous deal with UWM and would pay UWM the termination fee.

Although UWM had disclosed certain information about having hedged the transaction before March 27, investors did not learn the truth of the company's exposure until August 6, 2026. That day UWM reported three important things.

First, the company reported a massive $451 million net loss and roughly a $603 million hedging loss. Management revealed, apparently for the first time, that "we were over-hedged" and "obviously, the Two Harbors transaction went away."

Second, UWM disclosed that its total equity sequentially plunged by about $615 million, or a whopping 38%.

On top of that and third, UWM told shareholders in essence that, as a result of the foregoing, it entered into a massively dilutive recapitalization plan.

The market swiftly reacted, sending the price of UWM shares sharply lower that day. Between December 17, 2025, the day of the Two Harbors acquisition announcement, and August 6, 2026, the price Of UWM shares has declined by about $3.65 or 75%.

Hagens Berman's Investigation

"We're focused on UWM's explanations for why it refrained from unwinding its hedges months ago and why management seemingly went virtually silent on the naked hedging risks until recently," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in UWM and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding UWM should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

Matthias Bellino zahajuje novou offroadovou kapitolu díky Segway Powersports

PAŘÍŽ, 7. září 2026 /PRNewswire/ -- Francouzský šampion v enduru Mathias Bellino zahajuje novou kapitolu svého offroadového příběhu díky podpoře značky Segway Powersports, která jej vybavila čtyřkolkou Super Villain SX20T. Toto partnerství přináší Bellinovi nové příležitosti, jak zůstat v kontaktu s terénem, výzvami a objevováním neznáma, které utvářely jeho život v motosportu.

Bellino je vítězem Světového mistrovství juniorů v enduru (Enduro Junior World Championship) za rok 2012 a mistrovství v enduru E3 (Enduro E3 World Championship) za rok 2015. Byl také členem francouzského týmu, který vyhrál světový pohár juniorů ISDE (ISDE Junior World Trophy) v letech 2011-2013. Pochází z rodiny vyznávající hlubokou vášeň k motocyklům, na nichž začal jezdit již ve čtyřech letech a později se posunul k motokrosu a enduru na nejvyšší úrovni.

V srpnu 2018, kdy usiloval o účast na Dakar Rally, utrpěl při svém prvním etapovém závodě Desafío Ruta 40 nehodu s následkem vážného zranění páteře. Neštěstí sice ukončilo jeho profesionální závodní kariéru, ne však jeho vztah k motosportu. Později se vrátil do padoku EnduroGP jako manažer týmu Honda ORC a stále nachází nové způsoby, jak zůstat součástí offroadové komunity.

Se čtyřkolkou Super Villain SX20T nyní Bellino odhaluje novou příležitost k offroadovým zážitkům v terénu. Tato side by side čtyřkolka klade důraz právě na to, co ho k tomuto sportu vždy lákalo: pobyt venku, poznávání krajiny a sdílení zážitků s ostatními.

Pro Bellina není tato kapitola opakováním minulosti, ale další cestou vpřed podle vlastních pravidel. Značka Segway Powersports s ním sdílí víru v objevování neznáma a pod heslem Fear No Place (Nebát se nikam) jeho cestu podporuje.

O Segway Powersports

Společnost Segway je světovou jedničkou v oblasti mikromobility, powersportů a spotřebitelských robotů, proslulou svými inovacemi a důrazem na spotřebitele. Značka Segway Powersports se zaměřuje na vývoj a výrobu nové generace vozidel pro powersporty, včetně čtyřkolek ATV (all terrain vehicles) a SxS (side by side) pro pracovní i sportovní účely. Jako hi-tech společnost propojuje Segway Powersports robustní dodavatelský řetězec s vlastními výrobními kapacitami a spravuje celý životní cyklus výrobku od R&D a výroby až k prodeji a poprodejním službám.

Další informace najdete na https://powersports.segway.com.

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.

Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering (IPO) on or about February 13, 2025, and/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026 (the Class Period), are encouraged to contact our firm now.

Watch our video on the Aardvark investigation: youtu.be/pY5E36QoCqo

Key Case Details & Important Deadlines

- Lead Plaintiff Motion Deadline: October 13, 2026

- Visit: www.hbsslaw.com/aard

- Contact the Firm Now: [email protected]

844-916-0895

What is the Lawsuit About?

The complaint alleges that Aardvark Therapeutics, a clinical-stage biopharmaceutical company focused on developing small-molecule therapies targeting bitter taste receptors (TAS2Rs) such as ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS), made materially false and misleading statements and/or failed to disclose critical information.

Specifically, the action points out that the offering documents and defendants failed to disclose:

- That ARD-101 was significantly less safe than defendants had led investors to believe;

- That unexpected, reversible cardiac observations (such as QRS prolongation) occurred during trials at above-target doses; and

- Consequently, Aardvark's clinical, regulatory, and commercial prospects—including the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE)—were materially overstated.

The Truth Emerges: Voluntarily Pause and FDA Clinical Hold

- February 27, 2026: Aardvark announced it was voluntarily pausing its Phase 3 HERO trial due to "reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study." Following this news, Aardvark's stock price plummeted over 56%.

- May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and OLE trial. Aardvark's stock price fell another 32.1%.

Hagens Berman's Investigation

"We're investigating the suit's allegations, including that Aardvark allegedly misled investors about ARD-101's development, its safety and efficacy," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the claims in the pending suit.

What Can Aardvark Investors Do?

If you are a class member who suffered losses on Aardvark securities, you have until October 13, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. The firm welcomes AARD investors to contact the firm to discuss their legal rights and potential recovery options.

- Submit Your Information to Hagens Berman

- Contact an Attorney: [email protected]

844-916-0895

If you'd like more information and answers to frequently asked questions about the firm's Aardvark investigation, read more »

Whistleblowers: Persons with non-public information regarding Aardvark Therapeutics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Innventure, Inc. (NASDAQ: INV) and certain executives face a securities class action lawsuit after its stock price cratered 55% on August 14, 2026, triggered by the company's decisions to remove the DarkNX project from its 2026 forecast and suspend its revenue guidance.

As a result of these developments, national shareholders rights firm Hagens Berman is investigating claims that Innventure violated the federal securities laws. The firm encourages Innventure investors who suffered substantial losses to submit your losses now.

Class Period: Nov. 17, 2025 – Aug. 13, 2026

Lead Plaintiff Deadline: Oct. 27, 2026

Visit: www.hbsslaw.com/inv

Contact the Firm Now: [email protected]

                                         844-916-0895

Innventure, Inc. ($INV) Securities Class Action:

The litigation is focused on the propriety of Innventure's statements about Accelsius' arrangement with DarkNX, a purported global digital infrastructure company, under which DarkNX would deploy Accelsius' NeuCool technology across a new 300MW AI data center campus in Ontario, Canada.

More specifically, the company has characterized the project as "the largest two-phase, direct-to-chip deployment to date, signaling a major shift toward large-scale industry adoption of next-generation cooling." In addition, during the Class Period, Innventure assured investors that the DarkNX project is "proceeding as expected with initial deliveries expected in 2026."

The company's narrative began to come into question on May 28, 2026. That day, forensic research firm Morpheus Research published "Innventure: The Latest Iteration Of A Decades-Long Grift Propped Up By A Fake 300MW Data Center Deal." According to the Morpheus report, there was "zero evidence this project exists or that DarkNX has the team or funding to even contemplate such a project."

The report said "[a]ccording to a former Innventure executive, management was using 'false information' and revenue projections that were 'pure fiction' to solicit investments into Accelsius." Quoting a former Accelsius employee, when asked about DarkNX, the former employee reportedly said "'we've never heard of the company'" and "'there's no data center.'"

On August 13, 2026, Innventure's narrative fully unraveled, when the company revealed "that the deployment site identified in the DarkNX purchase order is no longer available." Accordingly, the company removed the DarkNX project from its internal bookings and suspended its 2026 revenue and cash flow expectations.

As a result of these revelations, between May 27, 2026 (the day before Morpheus' report) and August 14, 2026, the price of Innventure shares crumbled $4.795, or a whopping 74%.

"We're focused on whether Innventure may have intentionally or recklessly misled its shareholders about the viability of the DarkNX project," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in Innventure and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding Innventure should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct.

Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now.

Class Period: Aug. 4, 2025 – July 29, 2026

Lead Plaintiff Deadline: Nov. 2, 2026

Visit Hims Investigation Page: www.hbsslaw.com/hims

Direct Contact Email: [email protected]

Firm Telephone: 844-916-0895

Hims & Hers Health ($HIMS) Securities Class Action

The lawsuit is focused on the propriety of Hims' repeated assurances that "[w]e have developed and maintain policies and procedures with respect to health information and personal information that we use or disclose in connection with our operations, including the adoption of administrative, physical, and technical safeguards to protect such information."

The complaint alleges that Hims: (1) shared consumers' health information with third-party advertising platforms; (2) charges consumers for prescriptions almost immediately after they submit intake forms, despite telling them that they will be able to consult with a medical provider to find a treatment that is "right for them[;]" and (3) as a result, would be subject to heightened regulatory scrutiny and likely to incur fees and penalties.

What Drove the $HIMS July 29, 2026 Stock Crash? The FTC and State Lawsuit Breakdown

The securities class action cites the July 29, 2026 federal complaint filed against Hims by the FTC—alongside co-plaintiffs the State of Utah and the County of Los Angeles (representing California).

After an extensive investigation by the Commission, it contends that Hims engaged in:

- Deceptive Health Data Sharing: Despite extensive marketing campaigns emphasizing strict privacy, discreet telehealth consultations, and data protection, the complaint alleges that Hims surreptitiously shared sensitive user medical conditions and personal health data with third-party advertising giants, including Meta Platforms (Facebook) and Snap, via embedded tracking pixels and customer list matching.

- Subscription Billing & Cancellation Barriers (ROSCA Violations): The lawsuit accuses Hims of violating the Restore Online Shoppers' Confidence Act (ROSCA) by enrolling consumers in recurring subscription models without informed consent. According to regulators, consumers were billed for prescriptions almost immediately upon completing an intake form—long before receiving any consultation with a medical provider—while facing dark patterns and hidden cancellation options designed to prevent subscription termination.

The market swiftly reacted, sending the price of Hims shares down $4.32 (-14.7%) and erasing over $970 million from the company's market capitalization in a single day.

"We're focused on whether Hims may have intentionally misled investors about its business practices, including the adequacy of its internal controls, and financial ramifications of the alleged misconduct," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in HIMS and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding HIMS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

Mathias Bellino rozpoczyna nowy rozdział swojej przygody z jazdą terenową przy wsparciu Segway Powersports

PARYŻ, 7 września 2026 r. /PRNewswire/ -- Francuski mistrz enduro Mathias Bellino rozpoczyna nowy rozdział swojej przygody z jazdą terenową przy wsparciu Segway Powersports, które przekazało mu pojazd Super Villain SX20T. Współpraca daje Bellino nowy sposób na bycie blisko terenu, podejmowanie wyzwań i karmienie ducha odkrywcy, które przez lata kształtowały jego życie w sportach motorowych.

Bellino zdobył tytuł mistrza świata juniorów w enduro w 2012 r. oraz mistrza świata Enduro E3 w 2015 r. Był również członkiem reprezentacji Francji, która przez trzy kolejne lata, od 2011 do 2013 r., zdobywała ISDE Junior World Trophy. Wychował się w rodzinie silnie związanej z motocyklami. Zaczął jeździć w wieku czterech lat, a następnie rozwijał karierę poprzez motocross aż do rywalizacji na najwyższym poziomie w enduro.

W sierpniu 2018 r., podczas swojego pierwszego rajdu cross-country, Desafío Ruta 40 w Argentynie, Bellino uległ wypadkowi, w wyniku którego doznał poważnych urazów kręgosłupa. W tym czasie przygotowywał się do realizacji swojego celu, jakim był start w Rajdzie Dakar. Wypadek zakończył jego zawodową karierę wyścigową, ale nie jego związek ze sportami motorowymi. Później wrócił do padoku EnduroGP jako menedżer zespołu Honda ORC i nadal znajdował nowe sposoby, by pozostawać aktywną częścią środowiska off-roadowego.

Dzięki Super Villain SX20T Bellino odkrywa teraz nowy sposób przeżywania jazdy w terenie. Ten pojazd typu side-by-side pozwala mu skupić się na tym, co zawsze przyciągało go do tego sportu: przebywaniu na świeżym powietrzu, odczytywaniu ukształtowania terenu i dzieleniu tych doświadczeń z innymi.

Dla Bellino ten nowy etap nie polega na odtwarzaniu przeszłości, lecz na dalszym podążaniu naprzód na własnych zasadach. Segway Powersports wspiera go w tej drodze, opierając współpracę na wspólnej pasji do odkrywania i duchu „Fear No Place".

Segway Powersports

Segway jest światowym liderem w dziedzinie mikromobilności, pojazdów terenowych i rekreacyjnych (powersports) oraz robotyki konsumenckiej, znanym z innowacyjności i produktów projektowanych z myślą o użytkownikach. Segway Powersports koncentruje się w szczególności na projektowaniu i produkcji nowej generacji pojazdów rekreacyjno-użytkowych, w tym pojazdów terenowych ATV oraz pojazdów typu side-by-side (SxS), przeznaczonych zarówno do zastosowań użytkowych, jak i sportowych. Jako przedsiębiorstwo zaawansowanych technologii Segway Powersports łączy rozbudowany łańcuch dostaw z własnymi możliwościami produkcyjnymi, zarządzając całym cyklem życia produktów - od badań i rozwoju oraz produkcji po sprzedaż i obsługę posprzedażową.

Więcej informacji na stronie: https://powersports.segway.com.

Share this article

LOS ANGELES, Sept. 7, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Planet Fitness, Inc.

IF YOU SUFFERED A LOSS ON YOUR PLANET FITNESS, INC. INVESTMENTS, CLICK HERE BEFORE SEPTEMBER 14, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About? 

On May 7, 2026, Planet Fitness released its first quarter 2026 financial results, slashing same-store growth from 4-5% to only 1%, and completely withdrawing its long-term three-year growth algorithm it had introduced just six months prior, citing, among other things, an over-pivoted marketing campaign that failed to resonate with its core customer base, alongside external competition. The Company further disclosed that it was pausing its planned national rollout of its Black Card price increase to prioritize revitalizing new membership growth.

On this news, Planet Fitness's stock price fell $19.95, or 31.2%, to close at $44.01 per share on May 7, 2026, thereby injuring investors.

What's The Next Step?

Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist you in potentially pursuing claims to recover your loss.

If you wish to serve as lead plaintiff, you must move the Court no later than September 14, 2026. Please contact us to learn more about your rights and interests by clicking here, by email ([email protected]), or by telephone at 310-201-9150 (Toll-Free: 888-773-9224).

You may retain counsel of your choice. If you bought securities during the class period, you may take no action and remain an absent class member. No class has been certified yet.

Why Glancy Prongay Wolke & Rotter LLP?

GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm's recent successes, GPWR was named one of Law360's Securities Groups of the Year and ranked 2nd in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Glancy Prongay Wolke & Rotter LLP,

1925 Century Park East, Suite 2100,

Los Angeles, CA 90067

Charles Linehan

Email: [email protected]

Telephone: 310-201-9150

Toll-Free: 888-773-9224

Visit our website at: www.glancylaw.com.

SOURCE Glancy Prongay Wolke & Rotter LLP

Share this article

HYDERABAD, India, Sept. 7, 2026 /PRNewswire/ -- According to Mordor Intelligence, the global snack bars market size is projected to grow from $21.94 billion in 2026 to $32.66 billion by 2031, registering a CAGR of 8.28% during the forecast period (2026-2031). Growth is being supported by rising demand for convenient, portable nutrition products that fit into commuting, school, and fitness routines. At the same time, tightening standards around health claims and changing consumer expectations are pushing manufacturers toward lower-sugar and higher-protein formulations. Strategic consolidation is also reshaping the category, while supply pressures affecting pea, whey, and rice protein isolates are increasing the importance of sourcing strategies and formulation flexibility.

Snack Bars Market Key Growth Factors

Convenience and Portable Nutrition Expand Consumption Occasions

Snack bars are increasingly positioned as practical nutrition formats for consumers managing busy lifestyles. Their portability allows brands to address multiple consumption occasions, including commuting, school routines, between-meal snacking, and pre- or post-workout use. This flexibility is helping snack bars compete with traditional packaged snacks while broadening their relevance across demographic groups.

The shift toward portable formats is also encouraging manufacturers to diversify product portfolios across cereal and granola bars, protein and energy bars, and fruit and nut or seed bars. As consumers increasingly combine convenience with nutritional expectations, brands are using format and formulation innovation to capture more frequent consumption.

Health-Claim Standards Drive Reformulation Toward Higher-Value Products

Regulatory changes are accelerating reformulation across the snack bars industry. Tighter standards surrounding the use of health claims, alongside growing consumer scrutiny of sugar content and nutritional composition, are encouraging manufacturers to reduce sugar and increase protein content.

This shift is creating opportunities for premium formulations designed to combine convenience with specific nutritional benefits. Higher-protein products are particularly relevant as consumers increasingly seek snacks that align with fitness and wellness routines. However, rising costs and supply pressures for key protein isolates are forcing manufacturers to balance nutritional ambitions with margin management.

Protein Supply Pressures Reshape Procurement Strategies

The growing use of pea, whey, and rice protein isolates is creating a supply-side challenge for snack bar manufacturers. Higher demand for protein-rich formulations is increasing exposure to raw material availability and input-cost fluctuations, placing pressure on gross margins.

Manufacturers are responding by negotiating longer-term supply agreements and diversifying protein sources to reduce dependence on individual inputs. This procurement shift is becoming an increasingly important competitive factor as companies seek to maintain consistent product quality and protect margins while expanding protein-focused portfolios.

"As global food safety mandates and functional beverage demand reshape pH control requirements, our structural analysis maps shifting demand across synthetic and bio-based sourcing. Built on direct supply-chain auditing and objective volume tracking, this report equips commercial leaders with a verified, defensible foundation for strategic procurement and investment," says Bhavesh-Narasinha Varute, Senior Research Manager.

Snack Bars Market Recent Industry Developments

April 2026 – ITC Limited finalized its acquisition of control over SproutLife Foods (YogaBar), strengthening its position in energy and protein bars and adding scale behind a digital-first brand.

March 2026 – Ferrero agreed to acquire Brazil-based Bold Snacks, a premium protein snack company with a growing portfolio of protein bars, marking Ferrero's entry into the better-for-you segment in South America.

Snack Bars Market Segment Insights

By Product Type

- Cereal and Granola Bars

- Protein/Energy Bar

- Fruit and Nut/Seed Bar

By Nature

- Conventional

- Organic

By Packaging Format

- Single-Serve

- Multipack

By Distribution Channel

- Supermarkets and Hypermarkets

- Convenience Stores

- Online Retail

- Specialty Stores

- Other Distribution Channels

Snack Bars Market Regional Insights

North America remains a significant market for snack bars, supported by established snacking habits, strong demand for portable nutrition, and continued innovation in protein and wellness-oriented products. Regulatory developments are also influencing product formulation as manufacturers reassess nutritional profiles and health claims.

Europe remains an important market for premium and health-focused snack bars, with manufacturers responding to consumer demand for lower-sugar and nutritionally differentiated products. Regulatory and labeling requirements continue to influence how brands position products and develop new formulations.

Asia-Pacific represents a strong long-term growth opportunity as urbanization, rising disposable incomes, and changing lifestyles increase demand for convenient packaged nutrition. Expanding modern retail and e-commerce channels are improving access to snack bar products across emerging consumer markets.

Discover the latest trends, growth opportunities, and competitive developments in the Snack Bars Market: https://www.mordorintelligence.com/industry-reports/global-snack-bars-market?utm_source=prnewswire

Competitive Landscape

The snack bars market is increasingly competitive as established food companies expand their portfolios into higher-growth snack and nutrition categories. Competitive strategies are centered on product innovation, protein positioning, healthier formulations, brand development, and broader distribution.

Industry consolidation is also becoming more significant as major food manufacturers use acquisitions to strengthen their exposure to faster-growing snacking categories. At the same time, supply chain management is becoming a key differentiator as manufacturers navigate protein ingredient costs and availability. Companies capable of securing reliable inputs while maintaining attractive nutritional and sensory characteristics are positioned to strengthen their market presence.

Key Companies in the Snack Bars Market

- General Mills Inc.

- Kellogg Company

- Mars Incorporated

- Mondelēz International Inc.

- Nestlé SA

Explore More Industry Research by Mordor Intelligence

Snack Foods Market: The global snack foods market size is estimated at USD 292.01 billion in 2026 and is projected to reach USD 358.58 billion by 2031, growing at a 4.2% CAGR from its 2025 valuation of USD 280.24 billion. Category demand is driven by shifting eating patterns, where round-the-clock snacking occasions increasingly substitute for structured meals, supported by rapid quick-commerce fulfillment infrastructure. To comply with tightening HFSS marketing restrictions and extended producer responsibility (EPR) mandates, CPG manufacturers are directing capital into clean-label reformulations and recyclable barrier packaging.

Dairy Snack Market Size: The global dairy snack market is estimated to expand from USD 266.70 billion in 2026 to USD 346.24 billion by 2031, registering a 5.37% CAGR from its 2025 base of USD 253.11 billion. Market expansion reflects a bifurcation between volume-dominant cheese snacks and high-growth yogurt formats, propelled by protein-conscious consumers and demand for probiotic fortification. While cartons and tetra-packs command core throughput, dairy processors are scaling flexible resealable pouches and direct-to-consumer delivery models to capture affluent urban shoppers trading up to organic and artisanal SKUs.

Fruit Snacks Market Share: The global fruit snack market is estimated at USD 22.02 billion in 2025 and is projected to reach USD 32.50 billion by 2030, advancing at an 8.10% CAGR. Robust growth is propelled by consumer migration toward whole-food, functional nutrition and certified organic label claims that offer cleaner alternatives to conventional confectionery. While North America represents the largest regional market, Asia-Pacific is accelerating rapidly due to urbanization and food labeling reforms, encouraging manufacturers to introduce innovative fruit chips, bars, and pouch formats.

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For media inquiries or further information, please contact: 

[email protected] 

Mordor Intelligence Private Limited

https://www.mordorintelligence.com/

SOURCE Mordor Intelligence Private Limited

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.

The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys.

View our latest video summary of the allegations: youtu.be/rsW1-f8ARRs

Class Period: Aug. 1, 2025 – May 15, 2026

Lead Plaintiff Deadline: Sept. 14, 2026

Visit: www.hbsslaw.com/regn

Contact the Firm Now: [email protected]

                                       844-916-0895

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action:

The litigation is focused on the propriety of Regeneron's repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the "Study").

The Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.

The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study's preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely.

Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial's achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are "because the test arms are performing well."

The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that "t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months."

One prominent analyst reportedly questioned whether the decision was made because, in contrast to management's expressed confidence, the "underlying PFS benefit may be insufficient to show statistical significance."

Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to "slow event rates," occurred nearly six months ago, and was "submitted it to all the global regulatory authorities in November, December timeframe."

Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the "trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS)."

"We're focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn't really there," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims in the suit.

If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

If you'd like more information and answers to other frequently asked questions about the Regeneron case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has been filed after repeated surprise unit handpiece sales underperformance and gradual revelations of excess customer inventory levels driven by repeated, late-quarter, bulk discounts. The lawsuit seeks to represent investors who purchased or otherwise acquired PROCEPT common stock between February 28, 2024 and February 25, 2026.

National shareholders rights firm Hagens Berman is investigating legal claims that PROCEPT and the other Defendants violated the federal securities laws in their communications about sales of the company's single-use handpiece, a component of its proprietary Aquablation therapy used to treat patients with an enlarged prostate.

The firm encourages investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm's attorneys.

View our latest video summary of the allegations: youtu.be/N5u0rLr0QmA

Class Period: Feb. 28, 2024 – Feb. 25, 2026

Lead Plaintiff Deadline: Sept. 22, 2026

Visit: www.hbsslaw.com/prct

Contact the Firm Now: [email protected]

                                        844-916-0895

PROCEPT BioRobotics (PRCT) Securities Class Action:

The lawsuit alleges that during the Class Period, the defendants withheld crucial information from investors about PROCEPT's business, operations, and financial condition. Its focus is on the propriety of the company's statements and omissions related to handpiece sales practices in the U.S., including repeated touting of growth in those sales.

More specifically, the complaint alleges that (unknown to investors) the wrongdoing consisted of company's utilization of an extensive discount program to incentivize its customers to place bulk orders exceeding customers' procedures demands, pulling forward sales at the expense of future periods and, thereby, artificially inflating reported unit sales and revenues.

Investors began to learn the truth through a series of partial disclosures, each of which drove the price of PROCEPT shares sharply lower.

On August 6, 2025, PROCEPT announced its Q2 2025 financial results, revealing that the company's handpiece sales unexpectedly deteriorated, missing consensus estimates by a wide margin.

Then, on November 4, 2025 PROCEPT reported its Q3 2025 results, again missing expected handpiece unit sales. During the corresponding earnings call, management slashed annual handpiece unit sales guidance to allow for the "optimization of field inventory[,]" and said PROCEPT had not "been managing customer inventory[,]" adding that some customers were "probably carrying too much."

Finally, on February 25, 2026 PROCEPT announced Q4 2025 results. For the first time, the company disclosed the actual number of procedures in the field and revealed that U.S. handpiece sales materially exceeded procedures in each quarter since Q1 2023.

Of concern was that cumulative excess customer inventory of handpieces were over 10,000 units and U.S. handpiece sales sequentially cratered by 30%. Management then said that the company was eliminating its (previously undisclosed) bulk order discount program which was designed to incentivize customers to make large purchases during "the final weeks" of every quarter. The problem was the bulk order discount program essentially ate into future sales as customers already had excess inventories.

As a result of these events, by February 25, the price of PROCEPT shares had steadily declined by $22.06, or over 48% from the close on August 6, 2025.

"We're focused on whether PROCEPT may have intentionally pulled-in sales from future quarters to make it seem like the company was meeting expectations and, if so, whether the company had been sufficiently transparent in its investor communications," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in PROCEPT and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

If you'd like more information and answers to other frequently asked questions about the PROCEPT case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding PROCEPT should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article